Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer

ConditionsNeoplastic Syndromes, Hereditary Cancer Genetic Predisposition to Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeUp to 21

SponsorSydney Children's Hospitals Network

About this trial

Assessment of the utility of family-based (trio) whole-genome sequencing for cancer predisposition testing in sequential newly diagnosed paediatric and adolescent cancer patients

Eligibility criteria

Qualifiers

New diagnosis of malignancy

Age ≤ 21 years

Written informed consent

Participants (≥ 12 years)

Disqualifiers

None

Trial design

Treatments tested in this trial

Family-based whole genome sequencing

Treatment groups

270 Participants

are divided into 1 treatment group

Locations

John Hunter Children's Hospital2305, NewcastleNew South Wales, Australia

Sydney Children's Hospital2031, SydneyNew South Wales, Australia

The Children's Hospital at Westmead2145, SydneyNew South Wales, Australia

Sponsors and collaborators

Sydney Children's Hospitals Network

Lead sponsor

Children's Cancer Institute Australia

Collaborator

Source ClinicalTrials.gov